Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (2.568.426 €): Targeting RNA as an approach for treating retinal disease Hor26.08.2022 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Targeting RNA as an approach for treating retinal disease
Today, vision impairment up to total blindness represents an increasing global problem with significant social and economic impact upon affected patients and society as a whole. Despite the advancing of knowledge on their genetic basis, there is no effective cure for retinal diseases (RD) to date and therefore there is an urgent need to fill this gap. The present DN “Targeting RNA as an approach for treating retinal disease” (RETORNA) aims to treat RD by using RNA therapy. Among the research objectives, we will study different types of RNA that are expressed in retinal cells. By observing bioinformatic models, cell and tissue cultures, animal models, and human patients, we will be able to create RNA profiles for different RD. This screening will identify several targets that will be used as therapeutic approaches. Then, selected RNAs will be used to treat different RD, such as macular degeneration and retinitis pigmentosa. Furthermore, the potential economic and social impact of such strategies upon European countries will be studied, and the possibility of commercialization will be assessed. RETORNA proposes breakthrough research, distributed in 10 individual projects, performed by 10 Doctoral Candidates (DCs). Some of the most highly qualified European scientists of the field will supervise those DCs, who will be awarded with a PhD at the end of the program. Moreover, DCs will be provided with different transferable skills, necessary for starting successful careers in academia, but also in other areas: industry, public organizations, non-profit organizations, consultancy, etc. The RETORNA consortium consists of 8 beneficiaries, including 7 Universities and 1 Research Institute. The consortium will be managed by 5 different boards (research, managing, training, communication, and quality), all of them in continuous communication with the coordinator and with the general assembly.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Arthex Biotech SL | ? |
| ACADEMISCH ZIEKENHUIS LEIDEN | 274.370 € |
| Bahcesehir Universitesi | 219.168 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 260.539 € |
| Fondazione Telethon ETS | 259.438 € |
| Fundacion Universidad Catolica de Valencia San Vicente Martir | 503.942 € |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | 260.538 € |
| Universidad de Alicante | 503.942 € |
| UNIVERSITAET LEIPZIG | 0,00 € |
| University College Cork - National University of Ireland, Cork | 286.488 € |
Quelle: https://cordis.europa.eu/project/id/101073316
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Arthex Biotech SL, Paterna, Spanien.
Die Visualisierungen zu "Arthex Biotech SL - EU-Förderung (2.568.426 €): Targeting RNA as an approach for treating retinal disease"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
